Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

Phase 2

Terminated

Conditions: Non Alcoholic Steatohepatitis (NASH)

Interventions: Other: Placebo
Drug: Tropifexor
Drug: Licogliflozin

First Posted Date: 2019-08-22

Last Posted Date: 2025-01-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 234

Registration Number: NCT04065841

Locations: 🇺🇸
Gut PC Digestive Health Specialist, Dothan, Alabama, United States
🇺🇸
Integrity Clinical Rsh LLC, Doral, Florida, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

and more 27 locations

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Phase 2

Completed

Conditions: Pulmonary Sarcoidosis

Interventions: Drug: CMK389
Drug: Placebo

First Posted Date: 2019-08-21

Last Posted Date: 2025-04-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT04064242

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom
🇺🇸
Univ of Florida College of Medicine x, Gainesville, Florida, United States
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

and more 4 locations

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: PDR001

First Posted Date: 2019-08-16

Last Posted Date: 2025-05-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT04058756

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸
MD Anderson Cancer Center Uni of Te, Houston, Texas, United States

and more 1 locations

To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Brolucizumab
Drug: Aflibercept

First Posted Date: 2019-08-15

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 263

Registration Number: NCT04058067

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

Phase 2

Completed

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: Crizanlizuamb
Drug: Standard of Care

First Posted Date: 2019-08-12

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 58

Registration Number: NCT04053764

Locations: 🇺🇸
Univ of Tenn Health Sciences Ctr, Memphis, Tennessee, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom
🇺🇸
University of Illinois Hospital and Health Sciences System ., Chicago, Illinois, United States

and more 4 locations

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Phase 3

Completed

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: Brolucizumab 6mg
Drug: Aflibercept 2 mg

First Posted Date: 2019-08-06

Last Posted Date: 2024-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 397

Registration Number: NCT04047472

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

Phase 2

Terminated

Conditions: Sjögren Syndrome

Interventions: Drug: Remibrutinib
Drug: Placebo

First Posted Date: 2019-07-29

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 73

Registration Number: NCT04035668

Locations: 🇬🇧
Novartis Investigative Site, Tyne And Wear, United Kingdom

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Phase 3

Active, not recruiting

Conditions: Cardiovascular Disease and Lipoprotein(a)

Interventions: Drug: Placebo
Drug: TQJ230

First Posted Date: 2019-07-17

Last Posted Date: 2025-06-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8323

Registration Number: NCT04023552

Locations: 🇺🇸
SEC Clinical Research LLC, Andalusia, Alabama, United States
🇬🇧
Novartis Investigative Site, Wrexham, United Kingdom
🇺🇸
Mercy Gilbert Medical Center, Gilbert, Arizona, United States

and more 29 locations

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

Phase 4

Completed

Conditions: Heart Failure
Chagas Disease

Interventions: Drug: Enalapril
Drug: Sacubitril/valsartan

First Posted Date: 2019-07-17

Last Posted Date: 2025-05-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 918

Registration Number: NCT04023227

Locations: 🇲🇽
Novartis Investigative Site, Xalapa, Mexico

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Phase 3

Completed

Conditions: Age-related Macular Degeneration

Interventions: Biological: Aflibercept 2 mg
Biological: Brolucizumab 6 mg

First Posted Date: 2019-07-02

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 734

Registration Number: NCT04005352

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy